Inflammation and Autoimmunity

Rheumatoid Arthritis Mouse Model

Biocytogen has established stable rheumatoid arthritis (RA) mouse models in various strains, including C57BL/6, DBA, and BALB/c, ideal for preclinical drug efficacy studies.

We have developed a series of target-humanized mouse models for pharmacodynamic evaluation and research in autoimmune and inflammatory disease studies, supporting RA therapeutic development.

on this page

Related Resources

    Mouse Model of Rheumatoid Arthritis

    Rheumatoid arthritis (RA) is one of the most common autoimmune diseases, characterized by joint swelling, pain, and impaired mobility. In severe cases, RA can lead to disability, with pathological features such as synovial hyperplasia, cartilage damage, and bone erosion.

    Collagen-Induced Arthritis (CIA):

    Induced by immunization with type II collagen (CII), the primary component of articular cartilage. CIA mice develop autoimmune polyarthritis that mimics the clinical and histological features of human RA.

    Collagen Antibody-Induced Arthritis (CAIA):

    Triggered by injection of anti-collagen antibodies. This model has a rapid disease onset and is widely used for studying acute arthritis progression.

    Adjuvant-Induced Arthritis (AIA):

    Also known as Freund's adjuvant arthritis, reflects many of the clinical features of human RA and is divided into complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA), with CFA being the most studied autoimmune model of rheumatoid arthritis.

    To support the development of RA therapeutics, Biocytogen has established various stable and reliable RA mouse models across multiple strains (C57BL/6, DBA, and BALB/c). These models are suitable for evaluating the preclinical efficacy of drug candidates.

    Collagen Induced Arthritis (CIA) Model
    Establishment of CIA Mouse Model
    • Experimental Animals: C57BL/6 or DBA1, 10-13 weeks, mal
    • Modeling reagent: CII emulsion
    • Modeling method: Sensitization—Day 0 (red point)
      Challenge—Day 21 (yellow point)
    Readout
    Included tests Phenotype Body weight
    Clinical score
    Histopathology H&E(Paws)
    Optional tests Tissue homogenate Cytokines test
    Peripheral blood flow cytometry Flow cytometry assay
    Mice strains
    B-hIL6/hIL6R
    B-hTNFA/hTNFR2/hTNFR1
    B-hOX40hOX40L
    B-hCD40
    B-hPD1
    Clinical score Symptoms of CIA
    Score 0 Normal
    Score 1 Redness and swelling of one joint type (A, B, C)
    Score 2 Redness and swelling of both joint types (A, B, C)
    Score 3 Redness and swelling of the three joint types (A, B, C)
    Score 4 The whole paw is red and swollen to the maximum extent
    Joint types: A: interphalangeal joint B: metacarpophalangeal joint C: wrist and tarsal joint
    Collagen induced arthritis in DBA/1 and C57BL/6 mice

    Collagen induced arthritis. DBA/1 mice or C57BL/6 mice received CⅡ emulsion on day 0 (200 μg) and day 21 (200 μg). Body weight (A) and clinical score (B) were recorded twice a week after the second immunization, the incidence (C) of arthritis were calculated. At the endpoint, bone tissue were collected for H&E staining (D, E). Mean ± SEM, n=4-10. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

    Methotrexate alleviated CIA in C57BL/6 mice

    Effects of methotrexate on CIA mouse model.
    (A) mouse body weight change; (B) clinical score; (3) mouse morbidity. (D) pathological score; (E) H&E staining of pathological sections. Mean ± SEM (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

    Sirukumab (in house) alleviated CIA in B-hIL6/hIL6R mice

    Effects of anti-human IL-6 antibody sirukumab in CIA mouse model. (A) mouse body weight change; (B) clinical score. The results showed that after the model was successfully established, mice in the treatment group (G3, G4) treated with sirukumab antibody showed improved clinical scores in a dose-dependent manner. Histopathological examination was performed on the joints of the extremities at endpoint. (C) Hematoxylin and eosin (H&E) staining. (D) Score of arthritis histology. Mean ± SEM

    Collagen induced arthritis in TNFA/hTNFR2/hTNFR1 humanized mice (B-hTNFA/hTNFR2/hTNFR1 mice)

    The arthritis model was induced in B-hTNFA/hTNFR2/hTNFR1 mice and C57BL/6 mice using collagen (CII).
    (A) mouse body weight change; (B) clinical score. The results showed that the clinical score of B-hTNFA/hTNFR2/hTNFR1 mice was significantly increased, suggesting that the arthritis model was successfully established. Mean ± SEM.

    Pathological analysis after the establishment of arthritis in B-hTNFA/hTNFR2/hTNFR1 mice and C57BL/6 mice.
    (A) Pathological score; (B) H&E staining of pathological sections, (a)pannus; (b)inflammatory cell infiltration (c)synovial hyperplasia; (d)bone structure damage; (e) inflammatory cell in bone marrow. In the model group, subcutaneous mixed inflammatory cell infiltration, periarticular stenosis, articular cartilage and bone tissue destruction and other arthritic lesions were observed in all or part of the limb joints, suggesting that the arthritis model was successfully established. Mean ± SEM.

    Anti-human TNF-α antibody alleviated CIA in TNFA/hTNFR2/hTNFR1 humanized mice (B-hTNFA/hTNFR2/hTNFR1 mice)

    Effects of anti-human TNF-α antibody Adalimumab in CIA mouse model. (A)mouse body weight change; (B) clinical score. High dose of adalimumab treated animal in G4 had reduced clinical score compared to G2. (C) Joints of the animals were collected at study endpoint and stained with hematoxylin and eosin (H&E) staining and pathological score were shown (D). Mean ± SEM.

    Anti-OX40L antibody alleviated CIA in OX40/OX40L humanized mice (B-hOX40/hOX40L mice)

    Effects of anti-human OX40L antibody Amlitelimab on CIA mouse model.
    (A)Schematic diagram of experiment design;
    (B)clinical scores. Amlitelimab treatment(G3) reduced clinical score in CIA models. Data was shown as Mean±SEM, and analyzed using Two way ANOVA followed Dunnett compared with G2. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).(C) Joints of the animals were collected at study endpoint and stained with hematoxylin and eosin (H&E) staining and pathological score were shown (D). Data was shown as Mean±SEM, and analyzed using One way ANOVA followed Dunnett compared with G2. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

    Anti-CD40 antibody alleviated CIA in CD40 humanized mice (B-hCD40 mice)

    Effects of anti-human CD40 antibody in CIA mouse model.
    (A)Schematic diagram of experiment design; (B) clinical scores. (C) Incidence rate (D) Joints of the animals were collected at study endpoint and stained with hematoxylin and eosin (H&E) staining and pathological score were shown. Anti-CD40 treatment reduced incidence rate and clinical score in CIA animals (G4-G6). Data was shown as Mean±SEM, and analyzed using One way ANOVA followed Dunnett compared with G3. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). (E) Score of arthritis histology. (F) Animals body weight change. Data was shown as Mean±SEM, and analyzed using One way ANOVA followed multiple comparison with G3. (*p<0.0...

    Collagen induced arthritis in PD-1 humanized mice (B-hPD-1 mice)

    Collagen induced arthritis in B-hPD-1 mice. (A) clinical scores. (B) Incidence rate (C)Animals body weight change of B-hPD-1 mice after CIA modeling. Mean ± SEM.

    CIA mouse model in Biocytogen
    Mice Gender Incidence on Day28 Incidence on Day32
    B-hIL6/hIL6R mice M 34% 40%
    B-hTLR8 mice F 60% 50%
    B-hCD40 mice F 50% 50%
    B-hOX40/OX40L mice M 20% 60%
    B-hPD1 mice F 60% 60%
    M 60% 80%
    B-hTNFA/hTNFR2/hTNFR1 mice F 48% 55%
    M 80% 80%